Imatinib Terminated Phase 2 Trials for Leukemias Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00499889Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
NCT00415857Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
NCT00015847Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
NCT00022490Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
NCT01005914Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia